Endometrial Cancer - Pipeline Review, H2 2017

  • ID: 4432179
  • Report
  • 647 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Boehringer Ingelheim GmbH
  • GamaMabs Pharma SA
  • Immunomedics Inc
  • Moderna Therapeutics Inc
  • Puma Biotechnology Inc
  • MORE
Endometrial Cancer - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Pipeline Review, H2 2017, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 39, 41, 1 and 16 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 3 and 1 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Boehringer Ingelheim GmbH
  • GamaMabs Pharma SA
  • Immunomedics Inc
  • Moderna Therapeutics Inc
  • Puma Biotechnology Inc
  • MORE
Introduction

Endometrial Cancer - Overview

Endometrial Cancer - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Endometrial Cancer - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Endometrial Cancer - Companies Involved in Therapeutics Development

AbbVie Inc

Ability Pharmaceuticals SL

Advenchen Laboratories LLC

Aeterna Zentaris Inc

ArQule Inc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

BioNTech AG

Biscayne Pharmaceuticals Inc

Boehringer Ingelheim GmbH

CBT Pharmaceuticals Inc

Critical Outcome Technologies Inc

CytomX Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Galena Biopharma Inc

GamaMabs Pharma SA

Genmab A/S

GlaxoSmithKline Plc

Glycotope GmbH

Gradalis Inc

Horizon Pharma Plc

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Incyte Corp

Innate Pharma SA

Innovation Pharmaceuticals Inc

Karyopharm Therapeutics Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

Millennium Pharmaceuticals Inc

Moderna Therapeutics Inc

Novartis AG

OncoResponse Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

Pivot Pharmaceuticals Inc

PTC Therapeutics Inc

Puma Biotechnology Inc

Sanofi

Shenogen Pharma Group Ltd

Sigma-Tau SpA

Sutro Biopharma Inc

Syndax Pharmaceuticals Inc

Synthon Holdings BV

Taiho Pharmaceutical Co Ltd

Tesaro Inc

Vyriad Inc

Endometrial Cancer - Drug Profiles

212 Pb-TCMC-Trastuzumab - Drug Profile

2X-121 - Drug Profile

2X-131 - Drug Profile

ABTL-0812 - Drug Profile

AEZS-138 - Drug Profile

AL-3818 - Drug Profile

anetumab ravtansine - Drug Profile

ARN-3261 - Drug Profile

atezolizumab - Drug Profile

AV-203 - Drug Profile

avelumab - Drug Profile

AZD-5363 - Drug Profile

BAY-1082439 - Drug Profile

BAY-1895344 - Drug Profile

BGB-283 - Drug Profile

BGBA-317 - Drug Profile

BIS-1602 - Drug Profile

buparlisib hydrochloride - Drug Profile

cabozantinib s-malate - Drug Profile

CBT-501 - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

Cellular Immunotherapy for Ovarian and Endometrial Cancer - Drug Profile

Cellular Immunotherapy to Taregt HER-2 for Oncology - Drug Profile

COTI-2 - Drug Profile

cridanimod - Drug Profile

CX-2009 - Drug Profile

durvalumab - Drug Profile

durvalumab + tremelimumab - Drug Profile

emactuzumab - Drug Profile

endoxifen hydrochloride - Drug Profile

entinostat - Drug Profile

EP-100 - Drug Profile

EP-200 - Drug Profile

epacadostat - Drug Profile

everolimus - Drug Profile

FAZ-053 - Drug Profile

GALE-301 - Drug Profile

gedatolisib - Drug Profile

gemogenovatucel-T - Drug Profile

GM-102 - Drug Profile

GSK-2256098 - Drug Profile

GSK-2636771 - Drug Profile

HO-3867 - Drug Profile

HuMax-AXL-ADC - Drug Profile

IMCD-104C - Drug Profile

INCAGN-1876 - Drug Profile

INCAGN-1949 - Drug Profile

INCB-50465 - Drug Profile

INCB-54828 - Drug Profile

interferon gamma-1b - Drug Profile

itacitinib adipate - Drug Profile

Kevetrin - Drug Profile

lenvatinib mesylate - Drug Profile

lurbinectedin - Drug Profile

LY-3023414 - Drug Profile

M-9831 - Drug Profile

MCLA-128 - Drug Profile

MCS-110 - Drug Profile

miransertib - Drug Profile

mirvetuximab soravtansine - Drug Profile

MK-2206 - Drug Profile

MM-161 - Drug Profile

MM-310 - Drug Profile

monalizumab - Drug Profile

Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - Drug Profile

mRNA-4157 - Drug Profile

namitecan - Drug Profile

neratinib - Drug Profile

nintedanib - Drug Profile

niraparib - Drug Profile

nivolumab - Drug Profile

ONC-201 - Drug Profile

ONCO-101 - Drug Profile

Oncolytic Virus to Activate IFNb and SLC5A5 for Endometrial Cancer - Drug Profile

Oncolytic Virus to Activate IFNB and SLC5A5 for Hematological Malignancies - Drug Profile

Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile

ONCR-201 - Drug Profile

palbociclib - Drug Profile

PankoMab-GEX - Drug Profile

PDR-001 - Drug Profile

pembrolizumab - Drug Profile

Peptides to Antagonize GnRH II Receptor for Oncology - Drug Profile

pimasertib hydrochloride + voxtalisib - Drug Profile

PM-184 - Drug Profile

PRI-724 - Drug Profile

PTC-596 - Drug Profile

PVT-005 - Drug Profile

sacituzumab - Drug Profile

sapanisertib - Drug Profile

SAR-408701 - Drug Profile

SC-004 - Drug Profile

selinexor - Drug Profile

sirolimus albumin-bound - Drug Profile

Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma - Drug Profile

SNG-1153 - Drug Profile

SP-2509 - Drug Profile

Stem Cell Therapy to Activate SLC5A5 for Oncology - Drug Profile

STRO-002 - Drug Profile

TAS-117 - Drug Profile

tisotumab vedotin - Drug Profile

trametinib dimethyl sulfoxide + uprosertib - Drug Profile

trastuzumab duocarmazine - Drug Profile

TSR-042 - Drug Profile

vistusertib - Drug Profile

XMT-1536 - Drug Profile

Endometrial Cancer - Dormant Projects

Endometrial Cancer - Discontinued Products

Endometrial Cancer - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Endometrial Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Endometrial Cancer - Pipeline by AbbVie Inc, H2 2017

Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2017

Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017

Endometrial Cancer - Pipeline by Aeterna Zentaris Inc, H2 2017

Endometrial Cancer - Pipeline by ArQule Inc, H2 2017

Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2017

Endometrial Cancer - Pipeline by AstraZeneca Plc, H2 2017

Endometrial Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Endometrial Cancer - Pipeline by Bayer AG, H2 2017

Endometrial Cancer - Pipeline by BeiGene Ltd, H2 2017

Endometrial Cancer - Pipeline by BioNTech AG, H2 2017

Endometrial Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017

Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017

Endometrial Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017

Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017

Endometrial Cancer - Pipeline by CytomX Therapeutics Inc, H2 2017

Endometrial Cancer - Pipeline by Eisai Co Ltd, H2 2017

Endometrial Cancer - Pipeline by Eli Lilly and Co, H2 2017

Endometrial Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2017

Endometrial Cancer - Pipeline by Exelixis Inc, H2 2017

Endometrial Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Endometrial Cancer - Pipeline by Galena Biopharma Inc, H2 2017

Endometrial Cancer - Pipeline by GamaMabs Pharma SA, H2 2017

Endometrial Cancer - Pipeline by Genmab A/S, H2 2017

Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017

Endometrial Cancer - Pipeline by Glycotope GmbH, H2 2017

Endometrial Cancer - Pipeline by Gradalis Inc, H2 2017

Endometrial Cancer - Pipeline by Horizon Pharma Plc, H2 2017

Endometrial Cancer - Pipeline by Immunocore Ltd, H2 2017

Endometrial Cancer - Pipeline by ImmunoGen Inc, H2 2017

Endometrial Cancer - Pipeline by Immunomedics Inc, H2 2017

Endometrial Cancer - Pipeline by Incyte Corp, H2 2017

Endometrial Cancer - Pipeline by Innate Pharma SA, H2 2017

Endometrial Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017

Endometrial Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017

Endometrial Cancer - Pipeline by MedImmune LLC, H2 2017

Endometrial Cancer - Pipeline by Merck & Co Inc, H2 2017

Endometrial Cancer - Pipeline by Merck KGaA, H2 2017

Endometrial Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017

Endometrial Cancer - Pipeline by Mersana Therapeutics Inc, H2 2017

Endometrial Cancer - Pipeline by Merus NV, H2 2017

Endometrial Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Endometrial Cancer - Pipeline by Moderna Therapeutics Inc, H2 2017

Endometrial Cancer - Pipeline by Novartis AG, H2 2017

Endometrial Cancer - Pipeline by OncoResponse Inc, H2 2017

Endometrial Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Endometrial Cancer - Pipeline by Pfizer Inc, H2 2017

Endometrial Cancer - Pipeline by Pharma Mar SA, H2 2017

Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H2 2017

Endometrial Cancer - Pipeline by PTC Therapeutics Inc, H2 2017

Endometrial Cancer - Pipeline by Puma Biotechnology Inc, H2 2017

Endometrial Cancer - Pipeline by Sanofi, H2 2017

Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd, H2 2017

Endometrial Cancer - Pipeline by Sigma-Tau SpA, H2 2017

Endometrial Cancer - Pipeline by Sutro Biopharma Inc, H2 2017

Endometrial Cancer - Pipeline by Syndax Pharmaceuticals Inc, H2 2017

Endometrial Cancer - Pipeline by Synthon Holdings BV, H2 2017

Endometrial Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017

Endometrial Cancer - Pipeline by Tesaro Inc, H2 2017

Endometrial Cancer - Pipeline by Vyriad Inc, H2 2017

Endometrial Cancer - Dormant Projects, H2 2017

Endometrial Cancer - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Endometrial Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Ability Pharmaceuticals SL
  • Advenchen Laboratories LLC
  • Aeterna Zentaris Inc
  • ArQule Inc
  • Arrien Pharmaceuticals LLC
  • AstraZeneca Plc
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • BeiGene Ltd
  • BioNTech AG
  • Biscayne Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • CBT Pharmaceuticals Inc
  • Critical Outcome Technologies Inc
  • CytomX Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Galena Biopharma Inc
  • GamaMabs Pharma SA
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Glycotope GmbH
  • Gradalis Inc
  • Horizon Pharma Plc
  • Immunocore Ltd
  • ImmunoGen Inc
  • Immunomedics Inc
  • Incyte Corp
  • Innate Pharma SA
  • Innovation Pharmaceuticals Inc
  • Karyopharm Therapeutics Inc
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Mersana Therapeutics Inc
  • Merus NV
  • Millennium Pharmaceuticals Inc
  • Moderna Therapeutics Inc
  • Novartis AG
  • OncoResponse Inc
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Pivot Pharmaceuticals Inc
  • PTC Therapeutics Inc
  • Puma Biotechnology Inc
  • Sanofi
  • Shenogen Pharma Group Ltd
  • Sigma-Tau SpA
  • Sutro Biopharma Inc
  • Syndax Pharmaceuticals Inc
  • Synthon Holdings BV
  • Taiho Pharmaceutical Co Ltd
  • Tesaro Inc
  • Vyriad Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll